Publications (148,987)

Search

Long-Term Influence of Platelet-Rich Plasma (PRP) on Dental Implants after Maxillary Augmentation: Retrospective Clinical and Radiological Outcomes of a Randomized Controlled Clinical Trial

Attia S, Narberhaus C, Schaaf H, Streckbein P, Pons-Kuehnemann J, Schmitt C, Neukam FW, et al. (2020)

Journal article

A Randomized Phase II Study of Nivolumab Plus Ipilimumab Versus Standard of Care in Previously Untreated and Advanced Non-Clear Cell Renal Cell Carcinoma (Suniforecast)

Ahrens M, Escudier B, Boleti E, Grimm MO, Goupir MG, Barthelemy P, Gravis G, et al. (2020)

Conference contribution

Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab (CD-Bev) vs. Carboplatin/Gemcitabine/Bevacizumab (CG-BEV) in Patients with Recurrent Ovarian Cancer: a Prospective Randomized Phase iii Engot/GCiG-Intergroup Study (Ago Study Group, Ago-AUSTRiA, ANZGOG,GiNECO, SGCTG)

Hanker L, Harter P, Sehoul L, Rau J, Canzler U, Schmalfeldt B, Thiel F, et al. (2020)

Conference contribution

Phase III PAOLA-1/ENGOT-OV25 Trial: Olaparib Plus Bevacizumab (BEV) As Maintenance Therapy in Patients (PTS) with Newly Diagnosed, Advanced Ovarian Cancer (OC) Treated with Platinum-Based Chemotherapy (PCH) Plus Bev

De Gregorio N, Harter P, Sehouli L, Canzler U, Marme F, Buderath P, Lueck HJ, et al. (2020)

Conference contribution

Germline (G)BRCA1/2 Mutations (M) and Hematological Toxicities in Patients (PTS) with Triple Negative Breast Cancer (TNBC) Treated with Neoadjuvant Chemotherapy (NACT)

Furlanetto J, Moebus V, Schneeweiss A, Rhiem K, Tesch H, Blohmer JU, Luebbe K, et al. (2020)

Conference contribution

A Randomized, Double-Blind, Phase III Trial of Neoadjuvant Chemotherapy (NACT) with atezolizumab/Placebo in Patients with Triple-Negative Breast Cancer (TNBC) Followed by Adjuvant Continuation of atezolizumab/Placebo (Gepardouze)

Loibl S, Jackisch C, Seiler S, Rastogi P, Huober L, Denkert C, Schneeweiss A, et al. (2020)

Conference contribution

Feasibility and Satisfaction of Young Cancer Survivors Participating in Preventive Interventions. A Subgroup Analysis of the Care for CAYA Program (CFC-P)

Elmers S, Beitzen-Heineke A, Von Grundherr J, Jensen W, Koch B, Mann J, Salchow J, et al. (2020)

Conference contribution

Health Problems and Quality of Life of Young Cancer Survivors in the Comprehensive Care for CAYA Program

Elmers S, Beitzen-Heineke A, Von Grundherr J, Jensen W, Koch B, Mann J, Salchow J, et al. (2020)

Conference contribution

Serio - Side Effect Registry in Immuno-Oncology

Koutzamanidis R, Mentzer D, Knauss S, Broeckelmann PJ, Hassel JC, Ugurel-Becker S, Pavel ME, et al. (2020)

Conference contribution

Nilotinib (NIL) vs. NIL Plus Pegylated Interferon alpha2B (IFN) Induction and NIL or IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1+Chronic Myeloid Leukemia (CML) Patients (PTS) in Chronic Phase

Ernst T, Saussele S, Burchert A, Baerlocher GM, Bruemmendorf TH, La Rosee PG, Heim D, et al. (2020)

Conference contribution

‹ 1 ... 4,386 4,387 4,388 4,389 4,390 ... 14,899 ›